Brief: EUROAPI: to support Sanofi's mRNA Vaccine Platform with development of Lipid Nanoparticles

Euroapi SA

30/05/2022 06:04

May 30 (Reuters) - Euroapi  EAPI.PA /Sanofi  SASY.PA :
    * CDMO: EUROAPI SUPPORTS SANOFI’S MRNA VACCINE PLATFORM WITH
THE
DEVELOPMENT OF LIPID NANOPARTICLES
    * SANOFI DECIDED TO EXPAND ITS COLLABORATION WITH EUROAPI TO
BENEFIT FROM ITS SPECIFIC EXPERTISE IN BOTH CUSTOMED SYNTHESIS
BY COMPLEX CHEMISTRY AND QUALITY CONTROL BY ANALYTICS
    * LIPID DELIVERY SYSTEMS ARE KEY ENABLERS TO ENSURE MRNA IS
PROPERLY DELIVERED TO CELL AND REPRESENT A STRATEGIC COMPONENT
OF MRNA VACCINES
    * CDMO: EUROAPI SUPPORTS SANOFI’S MRNA VACCINE PLATFORM WITH
THE
DEVELOPMENT OF LIPID NANOPARTICLES
    * SANOFI DECIDED TO EXPAND ITS COLLABORATION WITH EUROAPI TO
BENEFIT FROM ITS SPECIFIC EXPERTISE IN BOTH CUSTOMED SYNTHESIS
BY COMPLEX CHEMISTRY AND QUALITY CONTROL BY ANALYTICS
    * WILL LEVERAGE ITS DEVELOPMENT AND PRODUCTION CAPABILITIES
IN
ORGANIC CHEMISTRY TO PROVIDE SANOFI WITH CLINICAL MATERIALS'
SUPPLY
    * EUROAPI WILL DEVELOP INNOVATIVE CHEMICAL SYNTHESIS ROUTES
AND
MANUFACTURE GMP BATCHES FOR SEVERAL SECOND-GENERATION CATIONIC
LIPIDS THROUGH CONTRACT DEVELOPMENT AND MANUFACTURING
ORGANIZATION ACTIVITY
    * As such, EUROAPI will focus on lipids that are currently
being
tested as part of Phase I/II clinical trials that will support
Sanofi’s mRNA vaccines platform, targeting indications including
Flu.

Source text for Eikon:  ID:nBw1N2Kl8a 
Further company coverage:  EAPI.PA 

 (Reporting by Sudip Kar-Gupta)
 ((sudip.kargupta@thomsonreuters.com;))